Johnson & Johnson (JNJ) Tops Q4 EPS by 1c, Offers FY20 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Cantor Fitzgerald Reiterates Overweight Rating on Johnson & Johnson (JNJ) Following 4Q
January 23, 2020 6:39 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $168.00 price target on Johnson & Johnson (NYSE: JNJ) following the company's 4Q earnings report. Chen continues to believe that upward earnings revisions to JNJ's Pharma business and multiple expansion, driven by diminishing headlines... More
Johnson & Johnson (JNJ) PT Raised to $170 at Credit Suisse
January 23, 2020 6:16 AM ESTCredit Suisse analyst Matt Miksic raised the price target on Johnson & Johnson (NYSE: JNJ) to $170.00 (from $163.00) while maintaining a Outperform rating.
The analyst comments "We continue to see strength in JNJs Pharma franchise and pipeline, and expect generic headwinds to ease in 2020 vs. 2019.... More
